Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells.
作者信息
Urbach Achia, Bar-Nur Ori, Daley George Q, Benvenisty Nissim
机构信息
Manton Center for Orphan Disease Research, Howard Hughes Medical Institute, Children's Hospital, Boston, MA, USA.
出版信息
Cell Stem Cell. 2010 May 7;6(5):407-11. doi: 10.1016/j.stem.2010.04.005.
Abstract
摘要
相似文献
1
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells.
Cell Stem Cell. 2010 May 7;6(5):407-11. doi: 10.1016/j.stem.2010.04.005.
2
The epigenetics of fragile X syndrome.
Cell Stem Cell. 2007 Nov;1(5):488-9. doi: 10.1016/j.stem.2007.10.017.
3
Human pluripotent stem cell models of Fragile X syndrome.
Mol Cell Neurosci. 2016 Jun;73:43-51. doi: 10.1016/j.mcn.2015.11.011. Epub 2015 Nov 27.
4
CGG-repeat dynamics and gene silencing in fragile X syndrome stem cells and stem cell-derived neurons.
Mol Autism. 2016 Oct 6;7:42. doi: 10.1186/s13229-016-0105-9. eCollection 2016.
5
Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis.
Cell Rep. 2021 Apr 13;35(2):108991. doi: 10.1016/j.celrep.2021.108991.
6
Integrated transcriptome analysis of human iPS cells derived from a fragile X syndrome patient during neuronal differentiation.
Sci China Life Sci. 2016 Nov;59(11):1093-1105. doi: 10.1007/s11427-016-0194-6. Epub 2016 Oct 11.
7
Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
PLoS One. 2011;6(10):e26203. doi: 10.1371/journal.pone.0026203. Epub 2011 Oct 12.
8
Loss of the fragile X mental retardation protein causes aberrant differentiation in human neural progenitor cells.
Sci Rep. 2018 Aug 2;8(1):11585. doi: 10.1038/s41598-018-30025-4.
9
Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives.
J Mol Cell Biol. 2012 Jun;4(3):180-3. doi: 10.1093/jmcb/mjs007. Epub 2012 Mar 19.
10
Fragile X Syndrome Pre-Clinical Research: Comparing Mouse- and Human-Based Models.
Methods Mol Biol. 2019;1942:155-162. doi: 10.1007/978-1-4939-9080-1_13.
引用本文的文献
1
Ascorbic Acid Ameliorates Molecular and Developmental Defects in Human-Induced Pluripotent Stem Cell and Cerebral Organoid Models of Fragile X Syndrome.
Int J Mol Sci. 2024 Nov 26;25(23):12718. doi: 10.3390/ijms252312718.
2
Efficient generation of human induced pluripotent stem cells from urine samples of patients with Fragile X syndrome.
Front Cell Dev Biol. 2024 Nov 22;12:1489190. doi: 10.3389/fcell.2024.1489190. eCollection 2024.
3
Comparing stem cells, transdifferentiation and brain organoids as tools for psychiatric research.
Transl Psychiatry. 2024 Feb 28;14(1):127. doi: 10.1038/s41398-024-02780-8.
4
Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome.
Cell. 2023 Dec 21;186(26):5840-5858.e36. doi: 10.1016/j.cell.2023.11.019.
5
Directly reprogrammed fragile X syndrome dorsal forebrain precursor cells generate cortical neurons exhibiting impaired neuronal maturation.
Front Cell Neurosci. 2023 Sep 21;17:1254412. doi: 10.3389/fncel.2023.1254412. eCollection 2023.
6
Neuropharmacology of human TERA2.cl.SP12 stem cell-derived neurons in ultra-long-term culture for antiseizure drug discovery.
Front Neurosci. 2023 Jun 15;17:1182720. doi: 10.3389/fnins.2023.1182720. eCollection 2023.
7
iPSCs-Derived Neurons and Brain Organoids from Patients.
Handb Exp Pharmacol. 2023;281:59-81. doi: 10.1007/164_2023_657.
8
Advances and Applications of Brain Organoids.
Neurosci Bull. 2023 Nov;39(11):1703-1716. doi: 10.1007/s12264-023-01065-2. Epub 2023 May 24.
9
Dysregulated cholesterol metabolism, aberrant excitability and altered cell cycle of astrocytes in fragile X syndrome.
Glia. 2023 May;71(5):1176-1196. doi: 10.1002/glia.24331. Epub 2023 Jan 3.
10
Transcriptomic Analysis of Human Fragile X Syndrome Neurons Reveals Neurite Outgrowth Modulation by the TGFβ/BMP Pathway.
Int J Mol Sci. 2022 Aug 17;23(16):9278. doi: 10.3390/ijms23169278.
本文引用的文献
1
Induced pluripotent stem cells and reprogramming: seeing the science through the hype.
Nat Rev Genet. 2009 Dec;10(12):878-83. doi: 10.1038/nrg2700. Epub 2009 Oct 27.
2
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells.
Nat Biotechnol. 2009 Nov;27(11):1033-7. doi: 10.1038/nbt.1580. Epub 2009 Oct 11.
3
Disease models from pluripotent stem cells.
Ann N Y Acad Sci. 2009 Sep;1176:191-6. doi: 10.1111/j.1749-6632.2009.04962.x.
4
Upping the ante: recent advances in direct reprogramming.
Mol Ther. 2009 Jun;17(6):947-53. doi: 10.1038/mt.2009.72. Epub 2009 Mar 31.
5
Broader implications of defining standards for the pluripotency of iPSCs.
Cell Stem Cell. 2009 Mar 6;4(3):200-1; author reply 202. doi: 10.1016/j.stem.2009.02.009.
6
Induced pluripotent stem cells: current progress and potential for regenerative medicine.
Trends Mol Med. 2009 Feb;15(2):59-68. doi: 10.1016/j.molmed.2008.12.003. Epub 2009 Jan 21.
7
Human embryonic stem cells reveal recurrent genomic instability at 20q11.21.
Nat Biotechnol. 2008 Dec;26(12):1364-6. doi: 10.1038/nbt.1509. Epub 2008 Nov 23.
8
Recurrent chromosomal abnormalities in human embryonic stem cells.
Nat Biotechnol. 2008 Dec;26(12):1361-3. doi: 10.1038/nbt.1510. Epub 2008 Nov 23.
9
The promise of human induced pluripotent stem cells for research and therapy.
Nat Rev Mol Cell Biol. 2008 Sep;9(9):725-9. doi: 10.1038/nrm2466.
10
Disease-specific induced pluripotent stem cells.
Cell. 2008 Sep 5;134(5):877-86. doi: 10.1016/j.cell.2008.07.041. Epub 2008 Aug 7.
Zotero 插件